Related Experiment Videos
[Molecular genetics and lipoprotein lipase deficiency]
L Foubert1, P Benlian, J L de Gennes
1Service d'endocrinologie-métabolisme, C.H.U. Pitié, Paris.
Bulletin De L'Academie Nationale De Medecine
|March 1, 1994
Summary
Lipoprotein lipase (LPL) deficiency causes familial chylomicronemia. Heterozygous carriers, unlike those with homozygous LPL deficiency, show an atherogenic lipid profile with lower HDL and higher triglycerides, suggesting increased cardiovascular risk.
Area of Science:
- Genetics
- Biochemistry
- Cardiovascular Disease
Context:
- Familial chylomicronemia, caused by lipoprotein lipase (LPL) deficiency, is a rare autosomal recessive disorder.
- Homozygous LPL deficiency is typically non-atherogenic, with asymptomatic heterozygotes.
- Thirty-five LPL gene mutations have been previously identified globally.
Purpose:
- To investigate the molecular basis of LPL deficiency in 18 homozygous probands from 12 families.
- To analyze the lipid profiles of LPL heterozygote carriers versus non-carriers.
- To determine if heterozygous LPL deficiency is associated with an atherogenic lipid profile.
Summary:
- The study identified 13 novel mutations in the LPL gene, including missense mutations, deletions, insertions, and duplications.
- PCR and enzymatic restriction were used to differentiate heterozygote carriers (n=35) from non-carriers (n=26).
- Heterozygote carriers exhibited significantly lower HDL cholesterol and higher triglyceride levels compared to non-carriers.
Impact:
- Heterozygous LPL deficiency is associated with an atherogenic lipid profile, characterized by reduced HDL cholesterol and elevated triglycerides.
- This finding suggests that LPL deficiency in heterozygotes may contribute to cardiovascular risk, contrary to previous assumptions.
- The prevalence of heterozygous LPL deficiency is estimated at approximately 1/500, indicating a potentially significant public health concern for atherosclerosis.